ACTIVE_NOT_RECRUITING

Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI

Talk to us

Conditions

Mild Cognitive Impairment

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators will conduct a tau PET scan in cognitively normal older adults and patients with Mild Cognitive Impairment (MCI), enrolled in the National Alzheimer's Coordinating Center (NACC) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).

Official Title

Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI

Quick Facts

Study Start:2020-03-11
Study Completion:2027-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT04251130

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Males and females ≥ 60 years of age.
  2. * Part of the NACC longitudinal cohort (IRB# 068200) of the PMC/ADCC with consensus conference designation of cognitively normal or Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) Possible or Probable.
  3. * NACC longitudinal visit completed or scheduled within 6 months before or after enrollment in this study.
  4. * Women must be post-menopausal or surgically sterile.
  5. * An amyloid PET scan, completed as a part of the NACC protocol (IRB# 825943), must be performed or scheduled within 12 months before or after the \[18F\]PI-2620 PET scan.
  6. * A brain MRI, completed as a part of NACC protocol (IRB# 068200), must be performed or scheduled within 6 months before or after the \[18F\]PI-2620 PET scan. Scan should be of adequate research quality, including 3 Tesla and/or 7 Tesla high-resolution imaging of MTL structure.
  1. * Have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
  2. * Have evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan.
  3. * Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician.
  4. * Have a history of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported.

Contacts and Locations

Principal Investigator

David Wolk, MD
PRINCIPAL_INVESTIGATOR
University of Pennsylvania

Study Locations (Sites)

University of Pennsylvania, School of Medicine
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: University of Pennsylvania

  • David Wolk, MD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-03-11
Study Completion Date2027-01

Study Record Updates

Study Start Date2020-03-11
Study Completion Date2027-01

Terms related to this study

Additional Relevant MeSH Terms

  • Mild Cognitive Impairment